Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PLA2G2C | Q5R387 | 2/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 6/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6168369 | 1.00 | KMT2A (0.49) | KMT2APOLBL3MBTL1NOD1MAPK1 | |
| SCHEMBL14744557 | 0.88 | KMT2A (0.64) | KMT2APOLBL3MBTL1NOD1MAPK1 | |
| SCHEMBL7447157 | 0.88 | FOLH1 (0.51) | NOD1ITGB3ITGA2BFOLH1 | |
| SCHEMBL4685971 | 0.85 | SIRT2 (0.43) | NOD1SMN1; SMN2PLA2G2CITGB3ITGA2B | |
| SCHEMBL4365404 | 0.85 | CTSK (0.45) | NOD1PLA2G2CITGB3ITGA2BFOLH1 | |
| SCHEMBL2014739 | 0.85 | CTSK (0.45) | NOD1PLA2G2CITGB3ITGA2BFOLH1 | |
| SCHEMBL8593917 | 0.84 | KMT2A (0.43) | KMT2APOLBL3MBTL1NOD1MAPK1 | |
| SCHEMBL16124669 | 0.84 | NOD1 (0.51) | NOD1PLA2G2CITGB3ITGA2BFOLH1 | |
| SCHEMBL14744559 | 0.83 | FOLH1 (0.42) | L3MBTL1NOD1SMN1; SMN2PLA2G2CITGB3 | |
| SCHEMBL18609110 | 0.83 | FOLH1 (0.53) | KMT2APOLBL3MBTL1NOD1PLA2G2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1224186-B1 | PYRIDYL-CONTAINING SPIROCYCLIC COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT PLATELET AGGREGATION | MILLENNIUM PHARM INC (US) | 2003-09-24 | — | — | EP | disclosed |
| US-20030055244-A1 | Pyridyl-containing spirocyclic compounds as inhibitors of fibrinogen-dependent platelet aggregation | MILLENNIUM PHARMACEUTICALS, INC. | 2003-03-20 | — | — | US | disclosed |
| EP-1224186-A2 | PYRIDYL-CONTAINING SPIROCYCLIC COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT PLATELET AGGREGATION | COR THERAPEUTICS, INC. (US) | 2002-07-24 | — | — | EP | disclosed |
| WO-2001030780-A2 | PYRIDYL-CONTAINING SPIROCYCLIC COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT PLATELET AGGREGATION | COR THERAPEUTICS, INC. (US) | 2001-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055244-A1 | Pyridyl-containing spirocyclic compounds as inhibitors of fibrinogen-dependent platelet aggregation | PF4, PFKP, FGB | KMT2A 4716/4885POLB 3718/4885L3MBTL1 4158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.